March 31, 2001 |
Ivax Corp. faces a revived legal challenge to its generic version of the top-selling Taxol cancer drug, after a federal appeals court told a trial judge to reexamine the Food and Drug Administration's approval of the Ivax product. The ruling is the latest in a multifaceted legal fight involving Ivax, Taxol manufacturer Bristol-Myers Squibb Co. and American BioScience Inc., which says it has a patented method to reduce the drug's side effects. The U.S. Court of Appeals for the D.C.
June 7, 1994
Ivax Corp. denied allegations of securities fraud contained in a lawsuit brought by the former chairman of McGaw Inc. Ivax, a Miami maker of generic drugs, said Friday that the lawsuit, filed Thursday in U.S. District Court in Santa Ana by former McGaw Chairman James M. Sweeney, is without merit. Both the corporation and Chairman Phillip Frost were named as defendants. "We intend to defend the suit vigorously," Ivax's general counsel, Armando A. Tabernilla, said in a statement.
January 15, 2002 |
Ivax Corp. said a U.S. District Court judge invalidated American BioScience Inc.'s patent claims on Ivax's generic version of Taxol, the latest in a long-running patent dispute over the cancer drug. Ivax last month asked the judge in Los Angeles to rule that a Taxol-related patent held by ABI was invalid because it didn't cover anything new. Ivax has accused the drug's original marketer, Bristol-Myers Squibb Co.
May 31, 1997 |
Troubled pharmaceutical concern Ivax Corp. plans to sell its Irvine-based McGaw unit for $320 million in cash, well below the $440 million it paid for the company three years ago. B. Braun of America Inc., the U.S. subsidiary of Germany's Braun Melsungen AG, will acquire McGaw, a major Orange County employer. Braun said it would pay up to $80 million more for the company over a period of years, depending on McGaw's financial performance.
June 15, 1993 |
Johnson Products Co., a hair care goods manufacturer that ranks among the nation's largest black-owned companies, said Monday that it has agreed to be acquired by pharmaceuticals producer Ivax Corp. in a transaction valued at between $61 million and $73 million. The buyout is considered a milestone in the entrepreneurial history of African-Americans because it involves one of the nation's most successful, high-profile black manufacturers.
October 13, 2000
* Germany's Deutsche Bank said it reached an agreement to acquire the 84% of National Discount Brokers Group Inc. it does not already own for $840 million, or $49 a share, a deal that values the brokerage at more than $1 billion. * * Ivax Corp., which makes a generic version of the cancer-fighting drug Taxol, said it would acquire the Mexico City-based pharmaceutical company Laboratorios Fustery for an undisclosed amount of cash and stock.